Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction
AssigneeFournier Laboratories Ireland Limited
InventorsGerald Francis Watts, David Alan Playford
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination of a peroxisome proliferator activated receptor (PPAR) activator and a benzoquinone and their use in treating and/or preventing disorders characterized by endothelial dysfunction, such as cardiovascular disease, strokes and myocardial infarction. According to a preferred embodiment of the invention the benzoquinone or precursor thereof is a ubiquinone or precursor thereof, more preferably, coenzyme Q10 or a precursor thereof, and the PPAR activator is a fibrate or a thiazolidinedione, more preferably fenofibrate.
Claims2
A method for treating a disorder characterized by endothelial dysfunction in a mammal, the method comprising:
- administering daily to the mammal a composition comprising:
- about 200 mg of fenofibrate or a pharmaceutically acceptable salt thereof;
- and
- about 200 mg of coenzyme Q10 or a pharmaceutically acceptable salt thereof;
- the disorder being cardiovascular disease, hypertension, stroke, myocardial infarction, peripheral vascular disease, macro angiopathy in the mammal with diabetes, or micro angiopathy in the mammal with diabetes.
Dependencies are inferred from the claim text.